(Q40601178)

21 September 2017

title

Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector (English)

1 reference

21 September 2017

0 references

Ulrich-Peter Rohr

1

1 reference

21 September 2017

Marc-Andre Wulf

2

1 reference

21 September 2017

Susanne Stahn

3

1 reference

21 September 2017

Florian Heyd

4

1 reference

21 September 2017

Ulrich Steidl

5

1 reference

21 September 2017

Roland Fenk

6

1 reference

21 September 2017

Bertram Opalka

7

1 reference

21 September 2017

Gerald Pitschke

8

1 reference

21 September 2017

Hans-Bernd Prisack

9

1 reference

21 September 2017

Hans Bojar

10

1 reference

21 September 2017

Rainer Haas

11

1 reference

21 September 2017

Ralf Kronenwett

12

1 reference

21 September 2017

publication date

1 December 2003

1 reference

21 September 2017

1 reference

21 September 2017

volume

10

1 reference

21 September 2017

issue

12

1 reference

21 September 2017

page(s)

898-906

1 reference

21 September 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Novel tools for production and purification of recombinant adenoassociated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Researchers and regulators reflect on first gene therapy death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

inferred from DOI database lookup

7 January 2021

based on heuristic

In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700643

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700643

1 reference

Dimensions Publication ID

21 September 2017

1019165189

0 references

1 reference